2. Academic Validation
  3. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation

Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation

  • EXCLI J. 2023 Jun 6:22:482-498. doi: 10.17179/excli2023-6129.
Ying Kao 1 2,  Chung-Hsing Chou 3,  Li-Chun Huang 4,  Chia-Kuang Tsai 3
Affiliations

Affiliations

  • 1 Division of Neurosurgery, Department of Surgery, Taipei City Hospital Zhongxing Branch, Taipei 10341, Taiwan.
  • 2 Taipei City University, Taipei 100234, Taiwan.
  • 3 Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
  • 4 Department of Biochemistry, National Defense Medical Center, Taipei 11490, Taiwan.
PMID: 37534227 DOI: 10.17179/excli2023-6129
Abstract

Glioblastoma (GBM) is the most common type of primary brain tumor. Patients with GBM have poor survival outcomes. Isolated components of Momordica charantia have Anticancer effects. However, the bioactivity of M. charantia extracts against GBM remains unknown. We tested four major extracts of M. charantia and found that momordicine I reduced glioma cell viability without serious cytotoxic effects on astrocytes. Momordicine I suppressed glioma cell colony formation, proliferation, migration, and invasion. Momordicine I also induced Apoptosis, intracellular Reactive Oxygen Species (ROS) production, and senescence in glioma cells. Moreover, momordicine I decreased the Oxidative Phosphorylation capacity of glioma cells and inhibited tumor sphere formation in temozolomide (TMZ)-resistant GBM cells. We further explored whether the antiglioma effect of momordicine I may be related to cell cycle modulation and DLGPA5 expression. Our results indicate that the cytotoxic effect of momordicine I on glioma cells suggests its potential therapeutic application to GBM treatment. See also Figure 1(Fig. 1).

Keywords

DLGPA5; Momordica charantia; Momordicine I; glioblastoma; oxidative phosphorylation capacity.

Figures
Products